Sarepta Therapeutics Inc SRPT 1.93% shares nearly doubled back in September after the FDA granted accelerated approval for the company’s first drug, EXONDYS 51. However, after conducting a round of due diligence by talking to private payers and other experts, Jefferies analyst Gena Wang believes EXONDYS 51 uptake may be delayed.

EXONDYS 51

Wang spoke to four private payers, three Medicaid experts and two Duchenne Muscular Dystrophy (DMD) experts. In addition, she reviewed published medical policies from 21 other private payers.

According to Jefferies, 3/5 national and 8/15 regional managed care organizations have either denied or limited their coverage of EXONDYS 51.

“There appears to be no legal consequence, according to KOLs, for payers (Medicaid and private) to restrict/deny coverage, citing clinical benefits as #1 criteria for coverage decisions and FDA approval status as secondary,” Wang explained.

She isn’t surprised by the push-back and expects the road ahead for EXONDYS 51 to be an uphill climb.

Push-Back

“Our analysis suggests…

Click here to continue reading

Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!